-
VERO Biotech’s GENOSYL® Delivery System recognized as a “Technological Breakthrough” at Premier, Inc.’s Annual Supplier Innovation Celebration
-
VERO Biotech’s Second Generation GENOSYL® Delivery System (DS) Receives FDA Approval in Anesthesia in the Surgical Suite
-
VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System
-
VERO Biotech Receives FDA Approval of its Third Generation Tankless Inhaled Nitric Oxide Delivery System
-
Georgia Bio Awards VERO Biotech the 2022 Golden Helix Innovation Award and Deal of the Year Award
-
VERO Biotech Receives Funding from MVM Partners to Accelerate Growth
-
VERO Biotech Issued a Software Correction for Version 2.2.3
-
New Publication Analyzes Interhospital Transport of Newborns Using VERO Biotech’s GENOSYL® Delivery System for the Delivery of Inhaled Nitric Oxide
-
Georgia Bio Awards 2021 Golden Helix to VERO Biotech for Best Deal of the Year
-
New Publication Explores Hidden Costs of Tank-Based Inhaled Nitric Oxide Delivery Systems
Contact Info
387 Nerem Street NW, Suite 125
Atlanta, Georgia 30313
Product Inquiries
To report an adverse event, product questions or complaints, other safety-related information or technical support for a company product
877-337-4118
Quick Links
Medical Inquiries
For medical inquiries, click on the Request Form below.
Cigna Machine Readable Files
This link leads to the machine-readable files that are made available in response to the federal Transparency in Coverage Rule and includes negotiated service rates and out-of- network allowed amounts between health plans and healthcare providers. The machine readable files are formatted to allow researchers, regulators, and application developers
Indication & Safety Information
GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.
- GENOSYL is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
- Abrupt discontinuation of GENOSYL (nitric oxide) gas, for inhalation may lead to worsening oxygenation and increasing pulmonary artery pressure.
- Methemoglobin, NO2 and PaO2 should be monitored during nitric oxide administration.
- In patients with pre-existing left ventricular dysfunction, GENOSYL may increase pulmonary capillary wedge pressure leading to pulmonary edema. The most common adverse reaction is hypotension.
- Nitric oxide donor compounds may have an additive effect with GENOSYL on the risk of developing methemoglobinemia.
- Only validated ventilator systems or nasal cannulas should be used in conjunction with GENOSYL.
- See package insert for additional Important Safety Information.